BMXX.Y logo

bioMérieux OTCPK:BMXX.Y Stock Report

Last Price

US$9.51

Market Cap

US$11.9b

7D

0%

1Y

n/a

Updated

05 Sep, 2023

Data

Company Financials +

BMXX.Y Stock Overview

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

BMXX.Y fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance2/6
Financial Health6/6
Dividends3/6

bioMérieux S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for bioMérieux
Historical stock prices
Current Share Price€9.51
52 Week High€10.85
52 Week Low€9.51
Beta0.18
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-90.58%

Recent News & Updates

Recent updates

Shareholder Returns

BMXX.YUS Medical EquipmentUS Market
7D0%0.5%1.6%
1Yn/a-0.3%26.3%

Return vs Industry: Insufficient data to determine how BMXX.Y performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how BMXX.Y performed against the US Market.

Price Volatility

Is BMXX.Y's price volatile compared to industry and market?
BMXX.Y volatility
BMXX.Y Average Weekly Movementn/a
Medical Equipment Industry Average Movement8.3%
Market Average Movement6.1%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.0%

Stable Share Price: BMXX.Y has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BMXX.Y's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
196312,846Pierre Bouludwww.biomerieux.com

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests.

bioMérieux S.A. Fundamentals Summary

How do bioMérieux's earnings and revenue compare to its market cap?
BMXX.Y fundamental statistics
Market capUS$11.89b
Earnings (TTM)US$414.06m
Revenue (TTM)US$3.97b

28.7x

P/E Ratio

3.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BMXX.Y income statement (TTM)
Revenue€3.70b
Cost of Revenue€1.63b
Gross Profit€2.07b
Other Expenses€1.68b
Earnings€385.90m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)3.27
Gross Margin55.93%
Net Profit Margin10.43%
Debt/Equity Ratio13.5%

How did BMXX.Y perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

26%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.